Athira Pharma Inc
Change company Symbol lookup
Select an option...
ATHA Athira Pharma Inc
BLDP Ballard Power Systems Inc
FOX Fox Corp
JNJ Johnson & Johnson
ERBB American Green Inc
PEGA Pegasystems Inc
NDRA ENDRA Life Sciences Inc
HIG-G Hartford Financial Services Group Inc
NLLSY Nel ASA
AHEXY Adecco Group AG
Go

Health Care : Pharmaceuticals |
Company profile

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company’s pipeline is built from its drug discovery platform, ATH platform and consists of a series of small molecules that are designed to target either the central nervous system (CNS), by crossing the blood brain barrier (BBB), or the peripheral nervous system. Its lead candidate, ATH-1017, is a subcutaneous administered, BBB-penetrating, small molecule hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) activator for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer’s disease (AD). The Company also has preclinical candidates for non-AD indications, including ATH-1018, which is being developed to address peripheral indications, and ATH-1019 / ATH-1020 compounds, which are being advanced to address neuropsychiatric indications.

Premarket

Last Trade
Delayed
$10.88
-0.06 (-0.55%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$10.94
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
100

10-day average volume:
317,888
100

Display:

Providers:

UpdateCancel
6 providers
Today's News, January 25, 2022
Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that patient dosing has begun in SHAPE, a Phase 2...(Globe Newswire)

January 05, 2022
Athira Pharma Provides 2022 Pipeline Outlook

Topline data from ACT-AD Phase 2 Alzheimer's disease study in 2Q22 LIFT-AD Phase 3 Alzheimer's disease study sample size increased to strengthen statistical power of co-key secondary endpoints and enhance the potential for a single pivotal clinical...(Globe Newswire)

November 10, 2021
Athira Pharma Reports Third Quarter 2021 Financial Results and Business Update

- Completed enrollment of ACT-AD trial with topline data expected in the first half of 2022; LIFT-AD is actively recruiting with topline data expected by the end of 2022 - - Presented program updates and baseline data from ATH-1017's ongoing Phase...(Globe Newswire)

Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in mild-to-moderate Alzheimer's Disease at CTAD Conference

- Balanced baseline characteristics in ACT-AD and LIFT-AD to date - - Topline data from ACT-AD trial targeted for first half of 2022 - Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small...(Globe Newswire)

November 08, 2021
Athira Pharma to Present at Upcoming Investor Conferences

-Stifel 2021 Virtual Healthcare Conference- - Jefferies 2021 London Healthcare Conference- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop...(Globe Newswire)

October 29, 2021
Athira Pharma to Host Educational Webinar on the Clinical Applications of ERP P300

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced it will host an educational webinar to review...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.